anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Carpal tunnel syndrome(CTS), a type of median nerve neuropathies, is the most common peripheral nerve entrapment syndrome. Most cases are idiopathic but CTS can be associated with rheumatologic disorders. There isn't any gold standard technique in diagnosis of CTS. Electrodiagnostic studies (EDS) are usually performed to confirm diagnose, to differentiate other diseases or to detect severity. But EDS have some disadvantages such as EDS are time consuming, uncomfortable, may require interventional procedures, can not directly assess the anatomy of the median nerve and its surrounding structures. For these reasons, the use of ultrasonography (US) in the diagnosis of carpal tunnel syndrome has been investigated for a long time. Most of them focused on the cross-sectional area(CSA) of median nerve. Fewer studies have investigated the vascularity of the median nerve. But there is conflict results because conventional Doppler techniques may fail to show small vessels or slow blood flow. Superb microvascular imaging (SMI) is a new ultrasound technology that can diferentiate blood flow signals from artifacts by using a new algorithm. In carpal tunnel syndrome hypervasularitation of median nerve has showed by SMI. To our best knowledge, there isn't any study assessing median nerve hypervascularity by using SMI in PsA. So we aimed to investigate median nerve hypervasculatitation in psoriatic arthritis (PsA) patients with CTS or without CTS by using SMI, then compare them with normal people.
Little is known about the patterning of multiple long-term conditions (MLTCs) by age, ethnicity and across conceptualisations of MLTCs (e.g. MLTCs with/without mental health conditions [MHCs]). We examined ethnic inequalities in age-related patterns of MLTCs, and combinations of physical and MHCs using the English GP Patient Survey and Clinical Practice Research Datalink. We described the association between MLTCs and age using multilevel regression models adjusting for sex and area-level deprivation with patients nested within GP practices. Similar analyses were repeated for MLTCs that include MHCs. We observed ethnic inequalities from middle-age onwards such as older Pakistani, Indian, Black Caribbean and Other ethnic people had increased risk of MLTCs compared to white British people, even after adjusting for area-level deprivation. Compared to white British people, Gypsy and Irish Travellers had higher levels of MLTCs across the age groups, and Chinese people had lower levels. Pakistani and Bangladeshi people aged 50-74 years were more likely than white people to report MLTCs that included MHCs. We find clear evidence of ethnic inequalities in MLTCs. The lower prevalence of MLTCs that include MHCs among some minoritised ethnic groups may be an underestimation due to underdiagnosis and/or inadequate primary care and requires further scrutiny.
PURPOSE: A marker for diagnosing lichen planus, Brn2, is provided to enhance expresison level of Brn2 gene in a tissue or cells with lichen planus. CONSTITUTION: A marker for diagnosing lichen planus contains Brn2 gene or protein. The Brn2 gene has a base sequence of sequence number 1. The Brn2 protein has an amino acid of sequence number 2. A composition for diagnosing lichen planus contains a material for measuring Brn2 gene or protein level. The materials are a primer or probe. A pharmaceutical composition for preventing or treating lichen planus contains an antisense having a compelmentery sequence with Brn2 sequence or siRNA oligonucleotide as an active ingredient.
An assay method is disclosed which makes it possible to determine the presence of a diseased related conformation of a protein (e.g., PrP Sc ) in a sample. A sample is divided into two portions and the first portion is cross-linked to a first solid support and then contacted with a labelled antibody which binds to a non-disease form of the protein with a higher degree of affinity (e.g, 4 to 30 fold higher) than to the disease form of the protein. The second portion is treated in a manner which causes any disease form of the protein to change conformation to a form with a higher binding affinity for the labelled antibody. The treated second portion is then bound to a second solid support and contacted with labelled antibody. The level of labelled antibody binding to a protein in the first and second portions is determined and the amounts measured in each are compared. The difference between the two measurements is an indication of whether the diseased related conformation of the protein was present in the sample.
Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
Poor functional outcome is associated with perihematomal edema (PHE) expansion after intracerebral hemorrhage (ICH). The inflammatory response is crucial for the onset and progression of PHE. This study aimed to determine the connection between admission neutrophil-lymphocyte ratio (NLR) and early PHE development. We retrospectively analyzed patients with ICH admitted to the Chaohu Affiliated Hospital of Anhui Medical University from January 2021 to December 2022. The primary outcome measure was absolute PHE, defined as the volume of the follow-up PHE minus admission PHE. A semiautomated measurement tool (3D Slicer) was used to calculate the volumes of cerebral hematoma and cerebral edema. Spearman's correlation analysis determined the relationship between NLR and absolute PHE. The multiple linear regression model was constructed to analyze the predictive relation of admission NLR on early PHE expansion. A total of 117 patients were included. The median hematoma and PHE volumes on admission were 9.38 mL (interquartile range [IQR], 4.53-19.54) and 3.54 mL (IQR, 1.33-7.1), respectively. The median absolute PHE was 2.26 mL (IQR, 1.25-4.23), and the median NLR was 3.10 (IQR, 2.26-3.86). Spearman's correlation test showed a positive correlation between admission NLR and absolute PHE (r = .548, P < .001). Multiple linear regression analyses suggested that for every 1-unit increase in admission NLR (B = .176, SE = .043, Beta = .275, P < .001), there was a 0.176 mL increase in absolute PHE. Admission neutrophil-to-lymphocyte ratio (NLR) significantly and positively predicted early perihematomal edema (PHE) expansion.
Drug Reaction with Eosinophilia andSystemicSymptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including clobazam.Theseevents can be fatal or life-threatening, particularly if diagnosis and treatment do not occur as early as possible. DRESS typically, although notexclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis,nephritis, hematological abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophilia is often present. Because thisdisorderis variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations ofhypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patientshouldbe evaluated immediately. Clobazam should be discontinued if an alternative etiology for the signs or symptoms cannot be established [see Contraindications (4)].
Gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days and gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days.
BACKGROUND: Breast cancer-related lymphedema (BCRL) poses a significant risk following sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND), particularly affecting ethnic minorities, with a twofold increased risk. Axillary reverse mapping (ARM), a novel technique, shows potential in reducing BCRL rates, yet its utility in ethnic minorities lacks sufficient exploration. Therefore, our study aims to investigate the utility and outcomes of ARM on BCRL in an ethnic diverse group.
METHODS: A retrospective chart review of ARM patients from January 2019 to July 2022 was conducted, monitoring patients over 24 months at 3-month intervals using SOZO® scores, with comparisons with preoperative baselines.
RESULTS: Of the 212 patients, 83% belonged to ethnic minorities. SLNB was performed in 83%, ALND in 17%, and 62.3% underwent radiation therapy. Positive lymph nodes were found in 31.6%, with 22.2% exhibiting blue nodes and 25.9% exhibiting blue lymphatics. Of identified blue nodes, 70.2% were excised, including 51.5% crossover nodes. Lymphedema occurred in 3 patients, resulting in a BCRL rate of 1.4%. Compared with an historical BCRL incidence of 40.4% following ALND in ethnic minorities, our study reported a significantly lower rate of 8% (p < 0.001).
CONCLUSION: The ARM procedure can significantly lower BCRL in ethnic minority groups. The combination of ARM and bioimpedance spectroscopy led to a remarkably low BCRL rate of 1.4%. Notably, none of the patients in our study developed an axillary recurrence at 24-month follow-up. Nevertheless, future studies with larger sample sizes are warranted to better understand the utility of the ARM technique in this population.
PROBLEM TO BE SOLVED: To unnecessitate applying a pack agent directly with one's fingers and to remove dirt on the surface of a skin by arranging a pair of sheet materials to separably stick to the pack agent so as to insert the pack agent of a nearly uniformed peel-off type. SOLUTION: The pack agent 12 is of a peel-off type to dry and peel off after applying to a face or a body. The advantage of this peel-off type pack agent is making a skin soft and moist and removing dirt on the surface of the skin at the time of drying and peeling off. A pair of separators 14 and 16 are constituted of resin films or sheet members such as paper and arranged so as to insert the pack agent 12. First and second silicone layers 18 and 20 are inserted between the respective separators 14, 16 and the pack agent 12. These first and second silicone layers 18 and 20 are arranged so as to facilitate peeling off the separators 14 and 16 with respect to the pack agent 12.
Inherited platelet disorders (IPDs) are a heterogeneous group of conditions that present significant challenges in diagnosis and management. Here, we report two cases of patients presenting with clinically significant bleeding but with unclear etiologies by conventional clinical laboratory testing. Further evaluation, utilizing a combination of high-dimensional multiplexed mass cytometry and genetic sequencing, revealed the underlying causes of bleeding in both cases, leading to definitive diagnoses. These cases underscore the potential utility of combined multimodal approaches in evaluating patients with bleeding disorders. Moreover, these high-parameter methods can offer substantial mechanistic insights and can enhance our understanding of the molecular pathogenesis of IPDs. Future studies involving larger patient cohorts are needed to further validate this strategy, directly comparing its diagnostic yield and accuracy with current clinical laboratory testing approaches, which can ultimately improve patient care.
The control group will be required to attend the diabetic foot clinic for their usual care for their diabetic foot ulcer with weekly review for a maximum of eight weeks. They will also have a follow up appointment 4 weeks after completion of treatment.
Subcutaneous Infusion Administration

The average daily dose of Deferoxamine Mesylate for injection is usually between 20 and 60 mg/kg. In general patients with serum ferritin level below 2,000 ng/mL require about 25 mg/kg/day. Patients with serum ferritin level between 2,000 and 3,000 ng/mL require about 35 mg/kg/day. Patients with higher serum ferritin may require up to 55 mg/kg/day. It is not advisable to regularly exceed an average daily dose of 50 mg/kg/day except when very intensive chelation is needed in patients who have completed growth. If ferritin levels fall below 1,000 ng/mL, the risk of Deferoxamine mesylate toxicity increases; it is important to monitor these patients particularly carefully and perhaps to consider lowering the total weekly dose. The doses specified here are the average daily doses. Since most patients use Deferoxamine mesylate less than 7 days a week, the actual dose per infusion usually differs from the average daily dose; e.g. if an average daily dose of 40 mg/kg/day is required and the patient wears the pump 5 nights a week, each infusion should contain 56 mg/kg. 

Slow subcutaneous infusion using a portable, light-weight infusion pump over a period of 8 to 12 hours is regarded as effective and especially convenient for ambulatory patients, but may also be given over a 24-hour period. Deferoxamine mesylate should normally be used with the pump 5 to 7 times a week. Deferoxamine mesylate is not formulated to support subcutaneous bolus injection.

Intravenous Administration

Deferoxamine Mesylate for injection can be administered intravenously if needed in patients with intravenous access.

The recommended dose of Deferoxamine Mesylate for injection in adults is 40 mg/kg/day to 50 mg/kg/day over 8 hours to 12 hours at a rate of up to 15 mg/kg/hour for 5 days to 7 days per week. Maximum dose is 60 mg/kg/day.

The recommended dose of Deferoxamine Mesylate for injection in pediatric patients is 20 mg/kg/day to 40 mg/kg/day over 8 hours to 12 hours for 5 days to 7 days per week. The maximum recommended daily dose is 40 mg/kg/day until growth (body weight and linear growth) has ceased. 

In case of missed doses, Deferoxamine Mesylate for injection may be administered prior to or following same day blood transfusion (for example, 1 gram over 4 hours on the day of transfusion); however, the contribution of this mode of administration to iron balance is limited. Deferoxamine Mesylate for injection should not be administered concurrently with the blood transfusion as this can lead to errors in interpreting side effects such as rash, anaphylaxis and hypotension.

Intramuscular Administration

If given intramuscularly, the recommended dose of Deferoxamine Mesylate for injection is 500 mg to 1,000 mg per day. The maximum recommended daily dose is 1,000 mg per day.
This study was a single-center, prospective, randomized controlled, two-arm study. This study will be conducted in the First Hospital of China Medical University. the investigators aimed to investigate the effects of different inspired oxygen concentrations in lung protective ventilation strategies on immediate postoperative atelectasis and intraoperative changes of oxygenation index in patients undergoing neurosurgical surgery in the supine position. A total of 96 neurosurgical patients under supine position were selected with an estimated operation time of more than 2 hours. Patients were randomly assigned to low-oxygen concentration (30%FiO2) L group, or high-oxygen concentration (60%FiO2) H group, and both groups received lung protective ventilation strategies. The main outcome was the comparison of postoperative atelectasis volume between the two groups. Secondary outcomes were the comparison of intraoperative oxygenation index and postoperative changes in diaphragm height between the two groups.
Wakeful Spanish is the Spanish-language version of Wakeful, developed at Northwestern University. It is a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs.
The invention relates to a lip or care stick which contains vitamins and which is used for cosmetic applications. The stick contains an outer complex comprised of a cellulose derivative having a particle size ranging from 0.5 to 100 μm, and is comprised of a phospholipid and of an α-tocopheral ester. The proportion of the complex is equal to 0.5 and 40 wt. %, with regard to the total mass. The stick also contains cosmetically conventional fats, waxes and additive which have a proportion ranging from 99.5 to 60 wt. % α-tocopheral is stabilized with regard to UV-filters, can also be dissolved in the form of the complex by moisture and can be absorbed and processed as a vitamin by the body.
In the clinical treatment of the patient for the first time, the upper left mediastinal tumor heart, thymus and esophagus are called connective tissues, the qi and blood accumulation is caused to be hard, the toxin and high temperature are activated to cause the lump to accumulate in the thymus, the soft tissue is enlarged to press nerves, and all tissues of the thoracic cavity are damaged and the functions are damaged. Antitoxic cooling traditional Chinese medicine: 30 kinds of Chinese medicinal materials including golden flower, asclepiadaceae, corydalis tuber, asparagus root, bean root, rabdosia, ginseng, bistort rhizome, meadowrue root and rhizome, rice bean, oldenlandia, sword bean, Chinese actinidia root, sancha glycoside, barbed skullcap herb, coix seed, rhubarb, tetrandra root, Chinese angelica root, gou Er tea, bitter orange, red peony root, etc. All the traditional Chinese medicines contain different biological components and are used for treating the symptoms. The main components are as follows: carotene and cryptoxanthin, and has effects of resisting oxidation, preventing tumor growth, and reducing cell injury and cancer cell metastasis. The butterfly prunetin has the functions of removing toxic substances, resisting inflammation and reducing cell necrosis. And (4) carrying out phosphoric acid deoxyenzyme, and cooling. Phosphonate dehydrogenase, rendering erythrocytes ineffective against oxidative damage, thus enhancing the resistance to phosphonate dehydrogenase; and the pristane is used for damp heat and preventing separation and transfer of color and body. The amphetamine is a carcinogen reducing substance, and is a carcinogenic source due to the strong ductility of the amphetamine.
PROBLEM TO BE SOLVED: To obtain the subject liquid medicine containing the vitamin B1 compound having improved stability in the liquid medicine by adding nitrate ion to the vitamin B1 compound. SOLUTION: This liquid medicine containing a vitamin B1 compound, especially the internal liquid medicine containing the vitamin B1 compound and having a pH of 2-6, is obtained by compounding (A) 1 mmol of the vitamin B1 compound (preferably thiamine, fursultiamine, etc.), with (B) 25-3,000 mmol of nitrate ion, and preferably further additionally with (C) an organic acid (for example, citric acid, malic acid) or an inorganic acid (for example, hydrochloric acid, phosphoric acid). The component B preferably originates from such a compound as to generate the nitrate ion, from a plant containing the nitrate ion or from a vegetable galenical containing the nitrate ion. The amount of the component A to be added to the liquid medicine is preferably 0.0002-0.03 W/V%.  The liquid medicine may be compounded with a sweetening agent (for example, sugar, fructose), various vitamins (for example, vitamin B2, vitamin B6), taurine, amino acids, etc.
The teachers and school-nurses in the control schools will conduct treatment as usual (TAU).The project offers a 2,5 hours presentation to the schools, providing general information about the research study, the prevalence of emotional disorders and how to handle emotional disorders in treatment as usual. No materials are provided by the project.
Inflammation is the human body's defence process against various pathogens, toxic substances, irradiation, and physically injured cells that have been damaged. Inflammation is characterized by swelling, pain, redness, heat, as well as diminished tissue function. Multiple important inflammatory markers determine the prognosis of inflammatory processes, which include likes of pro-inflammatory cytokines which are controlled by nuclear factor kappa-B (NF-kB), mitogen-activated protein kinase (MAPK), Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway, all of which are activated in response to the stimulation of specific receptors. Besides these, the cyclooxygenase (COX) enzyme family also plays a significant role in inflammation. The current review is kept forth to compile a summary of small molecules-based drugs approved by the USFDA during the study period of 2013-2023. A thorough discussion has also been made to focus on biologics, macromolecules, and small chemical entities approved during this study period and their greener synthetic routes with a brief discussion on the chemical spacing parameters of anti-inflammatory drugs. The compilation is expected to assist the medicinal chemist and the scientist actively engaged in drug discovery and development of anti-inflammatory agents from newer perspectives during the current years.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor that has excellent-inhibitory actions against both of hemagglutinin bonding activity and sialidase activity, which undesirable pathogenic viruses such as influenza virus have, and is useful for prevention and treatment of viral infections such as influenza by admixing a specific sialic acid derivative thereto. SOLUTION: This Pharmaceutical preparation includes a sialic acid derivative of the formula (Ac is acetyl), its alkali metal or alkaline earth metal salts or its ammonium salts. This preparation preferably contains the inhibitor in an amount of about 0.1-10 mg per the administration unit form in the nasal drop, about 0.1-1 mg in the injection solution in general. The daily dose of the preparation is about 0.2-15 mg/day/adult in 1-4 portions. For the prevention of influenza infection, the preparation is preferably dosed before the reveal of infection. The pharmaceutical preparation is also useful for treatment and/or prevention of the viral infections of mammalians other than human.
The present invention is directed to recombinant viruses containing a therapeutic transgene operably linked to a late regulatory element. The vectors of the present invention are capable of replication and lysis of neoplastic cells. The vectors may optionally include modifications to the genome so as to impart additional therapeutic, conditionally replicating or targeting functions. The present invention also provides pharmaceutical formulations of such vectors. The present invention further provides methods of use of such vectors. The present invention further provides methods of preparing the vectors.